Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo

Howard M. Ross, Edward A. Hirschowitz, Thomas J. Russi, Ronald Crystal, Sumihiko Nawata, Michael E. Burt, Murray F. Brennan, Jonathan J. Lewis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Local recurrence of sarcoma is due to residual tumor cells remaining after surgical resection and is associated with decreased survival. We implemented adenoviral-mediated transfer of the herpes simplex thymidine kinase (HSTK) gene with subsequent ganciclovir (GCV) administration to treat a model of residual sarcoma. [3H]Thymidine uptake in MCA sarcoma cells was determined after infection with replication incompetent adenovirus of the AdMLP.HSTK construct in the presence of GCV. In vivo efficacy was evaluated in a model of residual sarcoma when 9 mg of MCA tumor was implanted into the latissimus muscle of Fischer 344 rats. Three days after implantation, animals were randomized to receive AdMLP.HSTK, AdCMV.Null, or viral suspension buffer intratumorally. From Day 4, animals were administered b.i.d. GCV (50 mg/kg) or saline ip. Tumors were excised on Day 14 and weighed. Statistical analysis was by Mann-Whitney U test. In vitro: [3H]-thymidine incorporation was significantly decreased in MCA sarcoma cells infected with AdMLP.HSTK in the presence of GCV (P < 0.05). In vivo: Growth of MCA sarcoma treated with AdMLP.HSTK and GCV was significantly inhibited. Final tumor weights in the AdMLP.HSTK/GCV group were lower than all control groups (P < 0.05). A significant antitumor growth effect on MCA sarcoma was seen with adenoviral- mediated transfer of the HSTK gene and GCV administration, both in vitro and in an in vivo model of residual disease. This prodrug gene therapy strategy warrants investigation as an adjuvant modality in the management of sarcoma.

Original languageEnglish
Pages (from-to)7-11
Number of pages5
JournalJournal of Surgical Research
Volume70
Issue number1
DOIs
Publication statusPublished - 1 Jan 1997
Externally publishedYes

Fingerprint

Thymidine Kinase
Prodrugs
Herpes Simplex
Ganciclovir
Sarcoma
Genetic Therapy
Growth
Thymidine
Inbred F344 Rats
Residual Neoplasm
Nonparametric Statistics
Tumor Burden
Adenoviridae
Genes
Neoplasms
Suspensions
Buffers
Recurrence
Muscles
Control Groups

ASJC Scopus subject areas

  • Surgery

Cite this

Ross, H. M., Hirschowitz, E. A., Russi, T. J., Crystal, R., Nawata, S., Burt, M. E., ... Lewis, J. J. (1997). Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo. Journal of Surgical Research, 70(1), 7-11. https://doi.org/10.1006/jsre.1997.5113

Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo. / Ross, Howard M.; Hirschowitz, Edward A.; Russi, Thomas J.; Crystal, Ronald; Nawata, Sumihiko; Burt, Michael E.; Brennan, Murray F.; Lewis, Jonathan J.

In: Journal of Surgical Research, Vol. 70, No. 1, 01.01.1997, p. 7-11.

Research output: Contribution to journalArticle

Ross, HM, Hirschowitz, EA, Russi, TJ, Crystal, R, Nawata, S, Burt, ME, Brennan, MF & Lewis, JJ 1997, 'Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo', Journal of Surgical Research, vol. 70, no. 1, pp. 7-11. https://doi.org/10.1006/jsre.1997.5113
Ross, Howard M. ; Hirschowitz, Edward A. ; Russi, Thomas J. ; Crystal, Ronald ; Nawata, Sumihiko ; Burt, Michael E. ; Brennan, Murray F. ; Lewis, Jonathan J. / Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo. In: Journal of Surgical Research. 1997 ; Vol. 70, No. 1. pp. 7-11.
@article{24003a22d6a64b2ab4263e38d361b95b,
title = "Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo",
abstract = "Local recurrence of sarcoma is due to residual tumor cells remaining after surgical resection and is associated with decreased survival. We implemented adenoviral-mediated transfer of the herpes simplex thymidine kinase (HSTK) gene with subsequent ganciclovir (GCV) administration to treat a model of residual sarcoma. [3H]Thymidine uptake in MCA sarcoma cells was determined after infection with replication incompetent adenovirus of the AdMLP.HSTK construct in the presence of GCV. In vivo efficacy was evaluated in a model of residual sarcoma when 9 mg of MCA tumor was implanted into the latissimus muscle of Fischer 344 rats. Three days after implantation, animals were randomized to receive AdMLP.HSTK, AdCMV.Null, or viral suspension buffer intratumorally. From Day 4, animals were administered b.i.d. GCV (50 mg/kg) or saline ip. Tumors were excised on Day 14 and weighed. Statistical analysis was by Mann-Whitney U test. In vitro: [3H]-thymidine incorporation was significantly decreased in MCA sarcoma cells infected with AdMLP.HSTK in the presence of GCV (P < 0.05). In vivo: Growth of MCA sarcoma treated with AdMLP.HSTK and GCV was significantly inhibited. Final tumor weights in the AdMLP.HSTK/GCV group were lower than all control groups (P < 0.05). A significant antitumor growth effect on MCA sarcoma was seen with adenoviral- mediated transfer of the HSTK gene and GCV administration, both in vitro and in an in vivo model of residual disease. This prodrug gene therapy strategy warrants investigation as an adjuvant modality in the management of sarcoma.",
author = "Ross, {Howard M.} and Hirschowitz, {Edward A.} and Russi, {Thomas J.} and Ronald Crystal and Sumihiko Nawata and Burt, {Michael E.} and Brennan, {Murray F.} and Lewis, {Jonathan J.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1006/jsre.1997.5113",
language = "English",
volume = "70",
pages = "7--11",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo

AU - Ross, Howard M.

AU - Hirschowitz, Edward A.

AU - Russi, Thomas J.

AU - Crystal, Ronald

AU - Nawata, Sumihiko

AU - Burt, Michael E.

AU - Brennan, Murray F.

AU - Lewis, Jonathan J.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Local recurrence of sarcoma is due to residual tumor cells remaining after surgical resection and is associated with decreased survival. We implemented adenoviral-mediated transfer of the herpes simplex thymidine kinase (HSTK) gene with subsequent ganciclovir (GCV) administration to treat a model of residual sarcoma. [3H]Thymidine uptake in MCA sarcoma cells was determined after infection with replication incompetent adenovirus of the AdMLP.HSTK construct in the presence of GCV. In vivo efficacy was evaluated in a model of residual sarcoma when 9 mg of MCA tumor was implanted into the latissimus muscle of Fischer 344 rats. Three days after implantation, animals were randomized to receive AdMLP.HSTK, AdCMV.Null, or viral suspension buffer intratumorally. From Day 4, animals were administered b.i.d. GCV (50 mg/kg) or saline ip. Tumors were excised on Day 14 and weighed. Statistical analysis was by Mann-Whitney U test. In vitro: [3H]-thymidine incorporation was significantly decreased in MCA sarcoma cells infected with AdMLP.HSTK in the presence of GCV (P < 0.05). In vivo: Growth of MCA sarcoma treated with AdMLP.HSTK and GCV was significantly inhibited. Final tumor weights in the AdMLP.HSTK/GCV group were lower than all control groups (P < 0.05). A significant antitumor growth effect on MCA sarcoma was seen with adenoviral- mediated transfer of the HSTK gene and GCV administration, both in vitro and in an in vivo model of residual disease. This prodrug gene therapy strategy warrants investigation as an adjuvant modality in the management of sarcoma.

AB - Local recurrence of sarcoma is due to residual tumor cells remaining after surgical resection and is associated with decreased survival. We implemented adenoviral-mediated transfer of the herpes simplex thymidine kinase (HSTK) gene with subsequent ganciclovir (GCV) administration to treat a model of residual sarcoma. [3H]Thymidine uptake in MCA sarcoma cells was determined after infection with replication incompetent adenovirus of the AdMLP.HSTK construct in the presence of GCV. In vivo efficacy was evaluated in a model of residual sarcoma when 9 mg of MCA tumor was implanted into the latissimus muscle of Fischer 344 rats. Three days after implantation, animals were randomized to receive AdMLP.HSTK, AdCMV.Null, or viral suspension buffer intratumorally. From Day 4, animals were administered b.i.d. GCV (50 mg/kg) or saline ip. Tumors were excised on Day 14 and weighed. Statistical analysis was by Mann-Whitney U test. In vitro: [3H]-thymidine incorporation was significantly decreased in MCA sarcoma cells infected with AdMLP.HSTK in the presence of GCV (P < 0.05). In vivo: Growth of MCA sarcoma treated with AdMLP.HSTK and GCV was significantly inhibited. Final tumor weights in the AdMLP.HSTK/GCV group were lower than all control groups (P < 0.05). A significant antitumor growth effect on MCA sarcoma was seen with adenoviral- mediated transfer of the HSTK gene and GCV administration, both in vitro and in an in vivo model of residual disease. This prodrug gene therapy strategy warrants investigation as an adjuvant modality in the management of sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0031171394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031171394&partnerID=8YFLogxK

U2 - 10.1006/jsre.1997.5113

DO - 10.1006/jsre.1997.5113

M3 - Article

C2 - 9228920

AN - SCOPUS:0031171394

VL - 70

SP - 7

EP - 11

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -